ORG Wealth Partners’s Myriad Genetics MYGN Stock Holding History

ORG Wealth Partners’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$129	Buy	+30	New	+$127	﹤0.01%	2423

Other funds holding MYGN

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return

Mackenzie Financial Toronto Ontario, Ontario, Canada $91.6B AUM 30% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return

Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return

OP Asset Management Helsinki $11.8B AUM 34.59% 1-Year Est. Return

ORG Wealth Partners's MYGN Position: Q3 2026 in Review

ORG Wealth Partners opened a new position in Myriad Genetics (MYGN) in Q3 2026: 30 shares worth $129. The stake represents ﹤0.01% of the portfolio and ranks #2423 among its holdings.

83 funds tracked by Wall St. Rank hold MYGN as of Q3 2026.

ORG Wealth Partners held 30 shares of Myriad Genetics worth $129 as of Q3 2026.
Myriad Genetics was a new ORG Wealth Partners position in Q3 2026.
Myriad Genetics made up ﹤0.01% of ORG Wealth Partners's portfolio in Q3 2026, its #2423 holding.
83 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2026.

Based on ORG Wealth Partners's 13F filing for Q3 2026, filed 3 Nov 2026.